MedTrace Logo

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

NCT01770431 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1044

Last updated 2017-10-02

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.

Conditions

  • Hepatic Carcinoma

Interventions

DRUG

Huaier Granule

Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Qidong Gaitianli Medicines Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaoping Chen, Professor · Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770431 on ClinicalTrials.gov